Low DKA Risk Seen With Canagliflozin in Company Trials Low DKA Risk Seen With Canagliflozin in Company Trials

Janssen's analysis of data for more than 17,000 patients in its type 2 diabetes clinical-trial program for canagliflozin finds the risk for DKA is less than 1%. Medscape Medical News
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news